186 related articles for article (PubMed ID: 35078629)
1. Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: Lessons from a retrospective multicentric cohort of 383 patients.
Collard MK; Rullier E; Panis Y; Manceau G; Benoist S; Tuech JJ; Alves A; Laforest A; Mege D; Cazelles A; Beyer-Berjot L; Christou N; Cotte E; Lakkis Z; O'Connell L; Parc Y; Piessen G; Lefevre JH;
Surgery; 2022 May; 171(5):1193-1199. PubMed ID: 35078629
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with complete response of the tumour (ypT0) after neoadjuvant chemoradiotherapy and radical resection of rectal cancer.
Zhang H; Sun G; Zheng K; Lou Z; Gao XH; Meng RG; Furnée EJB; Zhang W
ANZ J Surg; 2021 Apr; 91(4):E190-E195. PubMed ID: 33559307
[TBL] [Abstract][Full Text] [Related]
5. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Jung SM; Yu CS; Park IJ; Kim TW; Kim JH; Yoon YS; Lim SB; Kim JC
Medicine (Baltimore); 2016 May; 95(20):e3718. PubMed ID: 27196490
[TBL] [Abstract][Full Text] [Related]
6. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
[TBL] [Abstract][Full Text] [Related]
7. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
8. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
9. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer.
Cho E; Park IJ; Hong SM; Lee JL; Kim CW; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2019 Jun; 18(2):e171-e178. PubMed ID: 31027968
[TBL] [Abstract][Full Text] [Related]
10. Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy.
Akeel N; Lan N; Stocchi L; Costedio MM; Dietz DW; Gorgun E; Kalady MF; Karagkounis G; Kessler H; Remzi FH
J Gastrointest Surg; 2017 Jan; 21(1):49-55. PubMed ID: 27796635
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Tominaga T; Akiyoshi T; Yamamoto N; Oba K; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Ueno M
Surgery; 2019 Dec; 166(6):1061-1067. PubMed ID: 31345564
[TBL] [Abstract][Full Text] [Related]
12. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of nodal involvement in rectal cancer after chemoradiotherapy.
Haak HE; Beets GL; Peeters K; Nelemans PJ; Valentini V; Rödel C; Kuo L; Calvo FA; Garcia-Aguilar J; Glynne-Jones R; Pucciarelli S; Suarez J; Theodoropoulos G; Biondo S; Lambregts DMJ; Beets-Tan RGH; Maas M
Br J Surg; 2021 Oct; 108(10):1251-1258. PubMed ID: 34240110
[TBL] [Abstract][Full Text] [Related]
14. [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].
Sprenger T; Rothe H; Beissbarth T; Conradi LC; Kauffels A; Homayounfar K; Behnes CL; Rödel C; Liersch T; Ghadimi M
Chirurg; 2016 Jul; 87(7):593-601. PubMed ID: 27106241
[TBL] [Abstract][Full Text] [Related]
15. Downstaged ypT0-2N0 rectal cancer after neoadjuvant chemoradiation therapy may not need adjuvant chemotherapy: a retrospective cohort study.
Liao YT; Lin YL; Huang J; Hung JS; Lin BR
Int J Colorectal Dis; 2021 Mar; 36(3):509-516. PubMed ID: 33128083
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy.
Bosch SL; Vermeer TA; West NP; Swellengrebel HA; Marijnen CA; Cats A; Verhoef C; van Lijnschoten I; de Wilt JH; Rutten HJ; Nagtegaal ID
Histopathology; 2016 Nov; 69(5):839-848. PubMed ID: 27270756
[TBL] [Abstract][Full Text] [Related]
17. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
18. An International Multicenter Prospective Study Evaluating the Long-term Oncological Impact of Adjuvant Chemotherapy in ypN+ Rectal Cancer.
Denost Q; Fleming CA; Burghgraef T; Celerier B; Geitenbeek R; Rullier E; Tuynman J; Consten E; Hompes R;
Ann Surg; 2023 Feb; 277(2):299-304. PubMed ID: 36305301
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
[No Abstract] [Full Text] [Related]
20. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
